25 / 154
351
ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Acta Neuropathol 121:397-405, 2011.
52. Kieran MW: Targeting BRAF in pediatric brain tumors. Am Soc
Clin Oncol Educ Book:e436-40, 2014.
53. Lawson AR, Tatevossian RG, Phipps KP, et al: RAF gene fusions
are specific to pilocytic astrocytoma in a broad paediatric
brain tumour cohort. Acta Neuropathol 120:271-3, 2010.
54. Jacob K, Albrecht S, Sollier C, et al: Duplication of 7q34 is
specific to juvenile pilocytic astrocytomas and a hallmark of
cerebellar and optic pathway tumours. Br J Cancer 101:722-
33, 2009.
55. Horbinski C: To BRAF or not to BRAF: is that even a question
anymore? J Neuropathol Exp Neurol 72:2-7, 2013.
56. Dahiya S, Emnett RJ, Haydon DH, et al: BRAF-V600E mutation
in pediatric and adult glioblastoma. Neuro Oncol 16:318-9,
2014.
57. Zhang J, Wu G, Miller CP, et al: Whole-genome sequencing
identifies genetic alterations in pediatric low-grade gliomas.
Nat Genet 45:602-12, 2013.
58. Penman CL, Faulkner C, Lowis SP, et al: Current Understanding
of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic
Targeting in Pediatric Low-Grade Gliomas. Front Oncol 5:54,
2015.
59. Schwartzentruber J, Korshunov A, Liu XY, et al: Driver
mutations in histone H3.3 and chromatin remodelling genes
in paediatric glioblastoma. Nature 482:226-31, 2012.
60. Wu G, Broniscer A, McEachron TA, et al: Somatic histone H3
alterations in pediatric diffuse intrinsic pontine gliomas and
non-brainstem glioblastomas. Nat Genet 44:251-3, 2012.
61. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al: K27M
mutation in histone H3.3 defines clinically and biologically
distinct subgroups of pediatric diffuse intrinsic pontine
gliomas. Acta Neuropathol 124:439-47, 2012.
62. Castel D, Philippe C, Calmon R, et al: Histone H3F3A and
HIST1H3B K27M mutations define two subgroups of diffuse
intrinsic pontine gliomas with different prognosis and
phenotypes. Acta Neuropathol 130:815-27, 2015.
63. Venneti S, Santi M, Felicella MM, et al: A sensitive and specific
histopathologic prognostic marker for H3F3A K27M mutant
pediatric glioblastomas. Acta Neuropathol 128:743-53,
2014.
64. Solomon DA, Wood MD, Tihan T, et al: Diffuse Midline
Gliomas with Histone H3-K27M Mutation: A Series of 47
Cases Assessing the Spectrum of Morphologic Variation and
Associated Genetic Alterations. Brain Pathol 26:569-80,
2016.
65. Ryall S, Buczkowicz P, Arnoldo A, et al: Abstract B12: H3-K27M
is a negative prognostic marker in high- and low-grade
pediatric thalamic glioma. Cancer Research 76:B12-B12,
2016.
66. Seton-Rogers S: Glioma: Targeting a histone mutant. Nat Rev
Cancer 15:2-2, 2015.
67. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N
Engl J Med 352:987-96, 2005.
68. Van den Bent M, Vogelbaum M, Erridge S, et al: ACTR-04.
results of the interim analysis of the eortc randomized phase
iii catnon trial on concurrent and adjuvant temozolomide in
anaplastic glioma without 1p/19q co-deletion, an intergroup
trial. Neuro-Oncology 18:vi1-vi2, 2016.
69. Wick W, Weller M, van den Bent M, et al: MGMT testing--the
challenges for biomarker-based glioma treatment. Nat Rev
Neurol 10:372-85, 2014.
70. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al:
Epithelioid GBMs show a high percentage of BRAF V600E
mutation. Am J Surg Pathol 37:685-98, 2013.
71. New P: An Unusual Case of Resistant Secondary Glioblastoma
with BRAF V600e Mutation (P3.279). Neurology 86, 2016.
72. Robinson GW, Orr BA, Gajjar A: Complete clinical regression
of a BRAF V600E-mutant pediatric glioblastoma multiforme
after BRAF inhibitor therapy. BMC Cancer 14:258, 2014.
73. Bautista F, Paci A, Minard-Colin V, et al: Vemurafenib in
pediatric patients with BRAFV600E mutated high-grade
gliomas, Pediatr Blood Cancer, 2013.
74. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib in
Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
New England Journal of Medicine 373:726-736, 2015.
75. Long GV, Stroyakovskiy D, Gogas H, et al: Combined BRAF and
MEK Inhibition versus BRAF Inhibition Alone in Melanoma.
New England Journal of Medicine 371:1877-1888, 2014.
76. Berghoff AS, Kiesel B, Widhalm G, et al: O6.02analysis of
pd1 and pd-l1 expression in glioblastoma. Neuro-Oncology
16:ii12-ii12, 2014.
77. Nduom EK, Wei J, Yaghi NK, et al: PD-L1 expression and
prognostic impact in glioblastoma. Neuro-Oncology 18:195-
205, 2016.
[CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS - Varun Monga, MBBS, et al]